US EditionUPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene ...
- On May 13, 2025, Azenta, Inc. Announced a strategic partnership between its GENEWIZ division and AI company Form Bio in Burlington, Massachusetts.
- The collaboration was established to advance gene therapy involving adeno-associated viruses by combining sequencing capabilities with AI-driven data analysis tools.
- GENEWIZ will supply synthesis, packaging, and long-read sequencing for AAV, while Form Bio provides genome integrity characterization and insights via its LAAVA software.
- Ginger Zhou of GENEWIZ highlighted that the partnership helps researchers navigate challenges more effectively and advance gene therapy development through enhanced data analysis.
- This partnership aims to accelerate timelines, reduce costs, and improve safety, efficacy, and manufacturability, officially launching at the May 2025 ASGCT meeting.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
All
Left
1
Center
9
Right
3
The Daily News - Jacksonville, NC+33 Reposted by 33 other sources
Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.
Safe, portable, and trackable instrument for transporting biological samples. - Automation Update
The liquid nitrogen vapor-based CryoPod Carrier from Azenta Life Sciences provides a safe, portable, and trackable solution for hand carrying temperature-sensitive materials between labs, providing protection below -150°C for over 3 hours. Adherence to cold-chain requirements for research and development can be challenging, particularly with temperature-sensitive biological products. There are multiple points throughout the cold chain where unre…
Coverage Details
Total News Sources36
Leaning Left1Leaning Right3Center9Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
C 69%
R 23%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage